Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Toll-like receptor 4 and Myeloid differentiation primary response gene 88 signaling pathway is a critical component of innate immunity. Toll-like receptor 4 (TLR4) is a transmembrane pattern recognition receptor that detects pathogen-associated molecular patterns such as bacterial lipopolysaccharide (LPS). Upon activation by its ligands, TLR recruits adaptor proteins including Myeloid differentiation primary response gene 88 (MyD88), which mediates signal transduction from activated receptors to downstream components through TIR domain interactions.[1] The canonical function involves two main pathways triggered by ligand binding: 1. The MyD88-dependent pathway: Activated at the plasma membrane by ligand-bound TLRs except for some endosomal receptors like TLR3. This leads to recruitment of adaptors such as TIRAP/Mal and ultimately results in activation of transcription factors NF-kB and AP1 via IRAK/TRAF6/TAK1 cascades. These transcription factors induce expression of pro-inflammatory cytokines including TNF-alpha and IL6.[2] 2. The TRIF-dependent pathway: Activated after internalization into endosomes; leads primarily to type I interferon production. Balanced activation between these pathways is crucial for appropriate immune responses against pathogens while avoiding excessive inflammation that could result in tissue damage or systemic complications like sepsis.[3] This signaling axis plays essential roles in host defense against infection but also contributes significantly to inflammatory diseases when dysregulated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Toll-like receptor 4 and Myeloid differentiation primary response gene 88 signaling pathway (TLR4/MyD88 pathway).